| NCF | Neutrophilic Chemotatic Factors |
|---|---|
| CDSRF | chronic disease and sociodemographic risk factors |
| CSPINE | corticosteroid use, seropositive RA, peripheral joint destruction, involvement of cervical nerves, n... |
| FI, FII, | etc. factors I, II, etc. |
| HFD | hemorrhagic fever of deer; high-fiber diet; high forceps delivery; hospital field director; human fa... |
| T-lymphocytes, suppressor-effector | Subpopulation of CD8+ T-lymphocytes which suppress antibody production or inhibit cellular immune responses. Suppressor-effector cells execute the message received from suppressor-inducer cells (T-lymphocytes, suppressor-inducer). (12 Dec 1998) |
|---|---|
| T-lymphocytes, suppressor-inducer | Subpopulation of CD4+ lymphocytes which induce CD8+ suppressor T-cells (T-lymphocytes, suppressor-effector) to suppress antibody production by B-cells. They also stimulate other cellular immune responses. (12 Dec 1998) |
| T suppressor cell | <haematology, immunology> Set of T lymphocytes (usually CD8) specifically involved in suppressing B-cell differentiation into antibody secreting cells. There may also be T suppresors of T-cell functions. (18 Nov 1997) |
| t-suppressor cell | A type of immune cells, also called t8 cells, these cells close down the immune response after it has destroyed invading organisms. T8 cells are sensitive to high concentrations of circulating lymphokine hormones and release their own lymphokines after an immune response has achieved its goal, signalling all other participants to cease their attack. Some memory B-cells remain to ward off a repeat attack by the invading organism. (12 Dec 1998) |
| tumour suppressor | <molecular biology, oncology> A gene that encodes a product that normally negatively regulates the cell cycle and that must be mutated or otherwise inactivated before a cell can proceed to rapid division. Examples: p53, RB retinoblastoma), WT 1 (Wilm's tumour), DCC (deleted in colonic carcinoma), NF 1 (neurofibrosarcoma) and APC adenomatous polyposis coli). (18 Nov 1997) |
| adjuvants, immunologic | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (12 Dec 1998) |
| receptors, immunologic | Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. (12 Dec 1998) |
| graft enhancement, immunologic | The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (12 Dec 1998) |
| monitoring, immunologic | Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc. (12 Dec 1998) |
| contraception, immunologic | Contraceptive methods utilizing immunologic processes. (12 Dec 1998) |
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
| desensitization, immunologic | Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity. (12 Dec 1998) |
| dose-response relationship, immunologic | A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. (12 Dec 1998) |
| immunologic | <immunology> Pertaining to immunology. (18 Nov 1997) |